The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Advancements in the field of Hodgkin lymphoma
Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, describes future developments in the Hodgkin lymphoma treatment landscape. Immunotherapy is playing an increasingly important role within Hodgkin lymphoma treatment. Brentuximab vedotin has demonstrated superior progression-free survival compared to conventional chemotherapies such as gemcitabine. Monoclonal antibodies including nivolumab and pembrolizumab are being recommended as combination therapies with chemotherapy or first-line therapy for treatment-naïve patients and Dr Desai additionally highlights the need for further treatment options for patients who progress on immunotherapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
